Abstract
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 140-148 |
| Number of pages | 9 |
| Journal | Journal of Neuroimmunology |
| Volume | 178 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Sep 2006 |
Fingerprint
Keywords
- Autoimmune disease
- Combination therapy
- EAE
- MS
- Statins
ASJC Scopus subject areas
- Immunology
- Clinical Neurology
- Immunology and Allergy
- Neurology
Cite this
Statins in the treatment of central nervous system autoimmune disease. / Weber, Martin S.; Youssef, Sawsan; Dunn, Shannon E.; Prod'homme, Thomas; Neuhaus, Oliver; Stuve, Olaf; Greenwood, John; Steinman, Lawrence; Zamvil, Scott S.
In: Journal of Neuroimmunology, Vol. 178, No. 1-2, 09.2006, p. 140-148.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Statins in the treatment of central nervous system autoimmune disease
AU - Weber, Martin S.
AU - Youssef, Sawsan
AU - Dunn, Shannon E.
AU - Prod'homme, Thomas
AU - Neuhaus, Oliver
AU - Stuve, Olaf
AU - Greenwood, John
AU - Steinman, Lawrence
AU - Zamvil, Scott S.
PY - 2006/9
Y1 - 2006/9
N2 - Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.
AB - Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.
KW - Autoimmune disease
KW - Combination therapy
KW - EAE
KW - MS
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=33748175510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748175510&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2006.06.006
DO - 10.1016/j.jneuroim.2006.06.006
M3 - Article
C2 - 16860400
AN - SCOPUS:33748175510
VL - 178
SP - 140
EP - 148
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
IS - 1-2
ER -